Protalix BioTherapeutics Inc (PLX)
2.27
+0.03
(+1.34%)
USD |
NYAM |
Jan 08, 16:00
2.265
0.00 (0.00%)
After-Hours: 20:00
Protalix BioTherapeutics SG&A Expense (Quarterly): 2.595M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Accuray Inc | 24.50M |
| AIM ImmunoTech Inc | 3.079M |
| Perspective Therapeutics Inc | 6.975M |
| Electromed Inc | 9.387M |
| Armata Pharmaceuticals Inc | 3.244M |